Video

Dr. Idos on Remaining Questions With Multiplex Panel Testing

Author(s):

Gregory E. Idos, MD
Conference|ASCO Annual Meeting

Gregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the remaining questions with multiplex panel testing as well as the cost effectiveness of it.

Gregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the cost effectiveness and other questions surrounding multiplex panel testing.

Currently, researchers are exploring the overall utility of how multiplex panel tests could potentially affect surgical management and chemotherapy prevention, Idos explains.

Regarding cost, using the gene-by-gene approach has been found to be more expensive than multiplex panel testing, he adds. Over the last few years, it has also been found that the cost of sequencing has gone down.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Related Content
Lynn M. Schuchter, MD, of Penn Medicine
July 16th 2024

ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers

Barbara Jane O’Brien, MD, of The University of Texas MD Anderson Cancer Center
June 21st 2024

Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasis

Allison Graeter, MD
June 12th 2024

Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies

Luis G. Paz-Ares, MD, PhD, chair, Medical Oncology Department, Hospital Universitario 12 de Octubre; associate professor, Universidad Complutense de Madrid
June 11th 2024

Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC

Lakshmi Nayak, MD, director, Center for CNS Lymphoma, Dana-Farber Cancer Institute; associate professor, neurology, Harvard Medical School
June 11th 2024

Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas

Craig E. Devoe, MD, MS
June 11th 2024

Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC